{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:23:06Z","timestamp":1792891386594,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schizophr"],"DOI":"10.1038\/s41537-024-00509-6","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T06:01:48Z","timestamp":1728021708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Real-world healthcare resource utilization, costs, and predictors of relapse among US patients with incident schizophrenia or schizoaffective disorder"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2966-0665","authenticated-orcid":false,"given":"Christopher L.","family":"Crowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia N.","family":"Pizzicato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Gloede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chen","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"509_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-015-0578-7","volume":"15","author":"JC Simeone","year":"2015","unstructured":"Simeone, J. C., Ward, A. J., Rotella, P., Collins, J. & Windisch, R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990-2013: a systematic literature review. BMC Psychiatry 15, 193 (2015).","journal-title":"BMC Psychiatry"},{"key":"509_CR2","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1080\/03007995.2021.1954894","volume":"37","author":"D Pilon","year":"2021","unstructured":"Pilon, D. et al. Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries. Curr. Med. Res. Opin. 37, 1811\u20131819 (2021).","journal-title":"Curr. Med. Res. Opin."},{"key":"509_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson, F. J. et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr. Bull. 44, 1195\u20131203 (2018).","journal-title":"Schizophr. Bull."},{"key":"509_CR4","unstructured":"Schizophrenia and Psychosis Action Alliance. Societal Costs of Schizophrenia & Related Disorders (2021)."},{"key":"509_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","volume":"64","author":"J Perala","year":"2007","unstructured":"Perala, J. et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry 64, 19\u201328 (2007).","journal-title":"Arch. Gen. Psychiatry"},{"key":"509_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.scog.2019.01.001","volume":"16","author":"LI Hartman","year":"2019","unstructured":"Hartman, L. I., Heinrichs, R. W. & Mashhadi, F. The continuing story of schizophrenia and schizoaffective disorder: one condition or two? Schizophr. Res. Cogn. 16, 36\u201342 (2019).","journal-title":"Schizophr. Res. Cogn."},{"key":"509_CR7","first-page":"18","volume":"7","author":"K Fitch","year":"2014","unstructured":"Fitch, K., Iwasaki, K. & Villa, K. F. Resource utilization and cost in a commercially insured population with schizophrenia. Am. Health Drug Benefits 7, 18\u201326 (2014).","journal-title":"Am. Health Drug Benefits"},{"key":"509_CR8","doi-asserted-by":"crossref","unstructured":"Kadakia, A. et al. The economic burden of schizophrenia in the United States. J. Clin. Psychiatry 83, 43278 (2022).","DOI":"10.4088\/JCP.22m14458"},{"key":"509_CR9","unstructured":"Wy, T. J. P. & Saadabadi, A. In StatPearls (StatPearls Publishing, 2023)."},{"key":"509_CR10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers, G. A. et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am. J. Psychiatry 177, 868\u2013872 (2020).","journal-title":"Am. J. Psychiatry"},{"key":"509_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pharmthera.2015.06.008","volume":"153","author":"EM Tsapakis","year":"2015","unstructured":"Tsapakis, E. M., Dimopoulou, T. & Tarazi, F. I. Clinical management of negative symptoms of schizophrenia: an update. Pharm. Ther. 153, 135\u2013147 (2015).","journal-title":"Pharm. Ther."},{"key":"509_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.pbb.2010.11.009","volume":"99","author":"DC Goff","year":"2011","unstructured":"Goff, D. C., Hill, M. & Barch, D. The treatment of cognitive impairment in schizophrenia. Pharm. Biochem. Behav. 99, 245\u2013253 (2011).","journal-title":"Pharm. Biochem. Behav."},{"key":"509_CR13","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1017\/S1461145712001277","volume":"16","author":"JP Zhang","year":"2013","unstructured":"Zhang, J. P. et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 16, 1205\u20131218 (2013).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"509_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-50","volume":"13","author":"R Emsley","year":"2013","unstructured":"Emsley, R., Chiliza, B., Asmal, L. & Harvey, B. H. The nature of relapse in schizophrenia. BMC Psychiatry 13, 50 (2013).","journal-title":"BMC Psychiatry"},{"key":"509_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.9758\/cpn.2011.9.2.45","volume":"9","author":"BJ Miller","year":"2011","unstructured":"Miller, B. J., Bodenheimer, C. & Crittenden, K. Second-generation antipsychotic discontinuation in first episode psychosis: an updated review. Clin. Psychopharmacol. Neurosci. 9, 45\u201353 (2011).","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"509_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-3-21","volume":"3","author":"H Liu-Seifert","year":"2005","unstructured":"Liu-Seifert, H., Adams, D. H. & Kinon, B. J. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 3, 21 (2005).","journal-title":"BMC Med."},{"key":"509_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2172","volume":"11","author":"P Huxley","year":"2021","unstructured":"Huxley, P. et al. Schizophrenia outcomes in the 21st century: a systematic review. Brain Behav. 11, e02172 (2021).","journal-title":"Brain Behav."},{"key":"509_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-10-2","volume":"10","author":"H Ascher-Svanum","year":"2010","unstructured":"Ascher-Svanum, H. et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 10, 2 (2010).","journal-title":"BMC Psychiatry"},{"key":"509_CR19","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40273-017-0515-3","volume":"35","author":"M Pennington","year":"2017","unstructured":"Pennington, M. & McCrone, P. The cost of relapse in schizophrenia. Pharmacoeconomics 35, 921\u2013936 (2017).","journal-title":"Pharmacoeconomics"},{"key":"509_CR20","first-page":"e373","volume":"25","author":"HC Waters","year":"2019","unstructured":"Waters, H. C., Ruetsch, C. & Tkacz, J. A claims-based algorithm to reduce relapse and cost in schizophrenia. Am. J. Manag. Care 25, e373\u2013e378 (2019).","journal-title":"Am. J. Manag. Care"},{"key":"509_CR21","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3111\/13696998.2013.841705","volume":"16","author":"MH Lafeuille","year":"2013","unstructured":"Lafeuille, M. H. et al. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J. Med. Econ. 16, 1290\u20131299 (2013).","journal-title":"J. Med. Econ."},{"key":"509_CR22","unstructured":"Bureau of Labor Statistics. Measuring Price Change in the CPI: Medical Care. https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm. (2023)."},{"key":"509_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1185\/03007991003658956","volume":"26","author":"D Nicholl","year":"2010","unstructured":"Nicholl, D., Akhras, K. S., Diels, J. & Schadrack, J. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr. Med Res. Opin. 26, 943\u2013955 (2010).","journal-title":"Curr. Med Res. Opin."},{"key":"509_CR24","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jpsychires.2012.05.001","volume":"46","author":"O Caseiro","year":"2012","unstructured":"Caseiro, O. et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J. Psychiatr. Res. 46, 1099\u20131105 (2012).","journal-title":"J. Psychiatr. Res."},{"key":"509_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.schres.2012.05.007","volume":"139","author":"M Alvarez-Jimenez","year":"2012","unstructured":"Alvarez-Jimenez, M. et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr. Res 139, 116\u2013128 (2012).","journal-title":"Schizophr. Res"},{"key":"509_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115529","volume":"330","author":"M Schlief","year":"2023","unstructured":"Schlief, M. et al. Ethnic differences in receipt of psychological interventions in Early Intervention in Psychosis services in England\u2014a cross-sectional study. Psychiatry Res. 330, 115529 (2023).","journal-title":"Psychiatry Res."},{"key":"509_CR27","doi-asserted-by":"crossref","unstructured":"Ziedan, E., Simon, K. I. & Wing, C. Effects of State COVID-19 Closure Policy on NON-COVID-19 Health Care Utilization. No. Working Paper 27621 (2020).","DOI":"10.3386\/w27621"}],"container-title":["Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41537-024-00509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-024-00509-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-024-00509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T06:04:57Z","timestamp":1728021897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41537-024-00509-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["509"],"URL":"https:\/\/doi.org\/10.1038\/s41537-024-00509-6","relation":{},"ISSN":["2754-6993"],"issn-type":[{"value":"2754-6993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.L.C., J.L.S., L.N.P., Y.Y., and C.T. were employees of Carelon Research at the time of the study, which received funding from Boehringer Ingelheim Pharmaceuticals, Inc. for the conduct of the study on which this manuscript is based. K.I. is an employee of Carelon Behavioral Health. C.L.C., J.L.S., and K.I. are Elevance Health shareholders. P.X. and T.G. are employees of Boehringer Ingelheim.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}